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Background: Chronic myeloid leukaemia (CML) is a clonal hae-
matopoietic stem-cell disorder. It was the first malignancy found
to be associated with a recurring chromosomal abnormality, Phil-
adelphia chromosome, resulting from translocation of genetic
material from one chromosome to another to form a fusion gene
(BCR/ABL). CML was the first disease in which the fusion gene was
recognised as giving rise to an abnormal fusion protein, funda-
mental in the pathogenesis of the disease. It is now the first dis-
order for which a therapeutic agent, imatinib mesylate (Glivec),
has been designed to specifically target the molecular defect, with
potential for cure.
Methods: This descriptive study was done at Nanakaly and
Hiwa hospitals in Erbil and Sulaimaniya, Iraq, from December 1,
2008, to June 30, 2009. A total of 100 patients with CML were ran-
domly selected. Clinical examination and laboratory investiga-
tions were done for all patients. Results were subjected to the
international Sokal scoring system and compared with other
studies.
Findings: The mean age of the study group was 42.8 ± 13.23
years (range 15–87). The male-to-female ratio was 1:1.08. The
most common symptoms at onset were fatigue, weight loss,
and abdominal fullness. At presentation, the mean white-cell
count was 164,000/lL, and the mean percentage of blast cells
was 3% in peripheral blood and 4% in marrow. Presence of the
Philadelphia chromosome and BCR/ABL gene was available for
18 cases and was positive for all. According to the International
Sokal Scoring System, patients were divided into three groups:
group A patients with good prognosis (91%), group B with moder-
ate prognosis (7%), and group C with poor prognosis (2%).
Interpretation: The mean age at presentation for CML in this
study was lower than in developed countries. Significant prognos-
tic indicators were platelet count, and peripheral and marrow
blast-cell percentage; a high count and high percentages were
associated with poor prognosis.
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Background: Olfactory neuroblastoma, also known as esthesio-
neuroblastoma, is a rare malignant tumour of the nasal cavity.
Diagnosis can be difficult and the disease can mimic other types
of sinonasal tract tumours. There has been only one case report
of this disease in Thai patients.
Methods: Olfactory neuroblastoma patients who were treated
at Ramathibodi Hospital from January, 2000, to October, 2010,
were identified and reviewed.
Findings: Nine patients medical records were reviewed; six
(66.7%) of the patients were male. Median age was 53 years (range
30–68) with peak incidence of olfactory neuroblastoma in the
sixth decade. The mean duration of symptoms prior to diagnosis
was 6.8 months (2–24). The most common presenting symptoms
were nasal obstruction (55%) and orbital symptoms (44%). 66% of
patients had Kadish stage C disease and the rest had stage B. One-
third of patients had nodal metastases initially, and all had locally
advanced disease. Four patients were initially misdiagnosed as
having undifferentiated or poorly differentiated carcinoma. Sur-
gery was done upfront in seven patients; five underwent postop-
erative radiotherapy. Chemotherapy as primary treatment was
given to two patients. With a median follow-up of 42 months
(5–115), the median overall survival of Kadish B patients was sig-
nificantly longer than Kadish C patients (not reached vs. 12.3
months, respectively; p = 0.04). None of patients with initial nodal
metastases survived longer than 13 months.
Interpretation: A high index of suspicion, especially in nasal
cavity tumours, and proper immunohistochemistry are essential
in the diagnosis of olfactory neuroblastoma. Kadish staging is
useful as a prognostic factor. Patients who presented with nodal
metastasis had very poor prognosis. A multidisciplinary team
approach may improve treatment outcome.
Funding: None.
The authors declared no conflicts of interest.
doi:10.1016/j.ejcsup.2011.02.023
P23 MANAGEMENT OF PATIENTS WITH NEGATIVE HEPATITIS B
SURFACE ANTIGEN AND POSITIVE ANTI-HEPATITIS B CORE
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Background: A substantial proportion of patients with negative
hepatitis B surface antigen (HBsAg) and positive anti-hepatitis B
core antibody (anti-HBcAb) have acute hepatitis after
chemotherapy.
Methods: Patients with negative HBsAg and positive anti-
HBcAb undergoing intensive chemotherapy for malignant lym-
phoma were recruited from 2007 to 2009. Hepatitis B virus DNA
was checked every 4 weeks during chemotherapy and every 8
weeks after completion of chemotherapy, for 1 year.
Findings: 20 patients were recruited. 13 patients had diffuse
large B-cell lymphoma. Three patients had Burkitt or Burkitt-like
lymphoma. Two patients had T-cell lymphoma and two had
another histological type. Mean age was 69 years (range 44–86).
Seven patients had stage I–II disease and 13 patients had stage
III–IV disease. Two patients died of primary refractory disease in
less than 1 year, without evidence of acute hepatitis. Three
patients who had a flare-up of acute hepatitis B were successfully
identified, and all recovered after anti-viral treatment, without
development of liver failure.
Interpretation: 16.6% of lymphoma patients with negative
HBsAg and positive anti-HBcAb had a flare-up of hepatitis B after
chemotherapy. Monitoring of hepatitis-B virus DNA every 4 weeks
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